Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (8)
Type
(
1 selected
)
Type
Guidance (284)
Guidance programme
(
1 selected
)
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (16)
Medical technologies guidance (7)
Technology appraisal guidance (284)
Apply filters
Showing 101 to 150 of 284
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Galcanezumab for migraine TS ID 10663
Technology appraisal guidance
Gantenerumab for treating early Alzheimer's disease TS ID 10668
Technology appraisal guidance
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394
Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]
Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A TS ID 9772
Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]
Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies TS ID 10330
Technology appraisal guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990
Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430
Technology appraisal guidance
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Technology appraisal guidance
Insulin icodec for treating type 1 and type 2 diabetes TS ID 11770
Technology appraisal guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190
Technology appraisal guidance
Iptacopan for treating complement 3 glomerulopathy TS ID 10435
Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949
Technology appraisal guidance
Isatuximab in combination for newly diagnosed multiple myeloma [ID3981]
Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822
Technology appraisal guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]
Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996
Technology appraisal guidance
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868
Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652
Technology appraisal guidance
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer TS ID 10203
Technology appraisal guidance
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis TS ID 10136
Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Technology appraisal guidance
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970
Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]
Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]
Technology appraisal guidance
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]
Technology appraisal guidance
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728
Technology appraisal guidance
Mavorixafor for treating WHIM syndrome ID3946
Technology appraisal guidance
Mepolizumab for treating chronic obstructive pulmonary disease [ID1237]
Technology appraisal guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400
Technology appraisal guidance
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730
Technology appraisal guidance
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer TS ID 11926
Technology appraisal guidance
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]
Technology appraisal guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777
Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593
Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis TS ID 11958
Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523
Technology appraisal guidance
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]
Technology appraisal guidance
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]
Technology appraisal guidance
Nitazoxanide for treating the common cold in people 12 years and over TS ID 10548
Technology appraisal guidance
Previous page
1
2
Current page
3
4
5
6
Page
3
of
6
Next page
Results per page
10
25
50
All
Back to top